NCT00353067View on ClinicalTrials.gov

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

PHASE3SuspendedINTERVENTIONAL

Enrollment

3,450

Participants

Timeline

Start Date

May 31, 2006

Conditions

Acute Coronary Syndrome

Interventions

DRUG

veliflapon (DG-031)

Trial Locations (11)

19142

Philadelphia

23434

Suffolk

23860

Hopewell

32216

Jacksonville

36106

Montgomery

37203

Nashville

60160

Melrose Park

73103

Oklahoma City

75007

Carrollton

75080

Richardson

76104

Fort Worth

Sponsors

Lead Sponsor

deCODE genetics

Collaborators (1)

Duke University

All Listed Sponsors

collaborator

Henry Ford Health System

OTHER

collaborator

Duke University

OTHER

lead

deCODE genetics

INDUSTRY